3 Stocks Moving The Health Care Sector Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 55 points (0.3%) at 16,707 as of Thursday, Aug. 14, 2014, 3:55 PM ET. The NYSE advances/declines ratio sits at 1,989 issues advancing vs. 996 declining with 174 unchanged.

The Health Care sector as a whole closed the day up 0.6% versus the S&P 500, which was up 0.4%. Top gainers within the Health Care sector included Vision-Sciences ( VSCI), up 2.2%, VirtualScopics ( VSCP), up 2.9%, Pro-Dex ( PDEX), up 5.0%, China Pharma ( CPHI), up 4.5% and Oragenics ( OGEN), up 1.8%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the sector higher today:

China Pharma ( CPHI) is one of the companies that pushed the Health Care sector higher today. China Pharma was up $0.01 (4.5%) to $0.32 on light volume. Throughout the day, 62,700 shares of China Pharma exchanged hands as compared to its average daily volume of 84,600 shares. The stock ranged in a price between $0.31-$0.33 after having opened the day at $0.33 as compared to the previous trading day's close of $0.31.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. China Pharma has a market cap of $14.2 million and is part of the health services industry. Shares are down 10.1% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate China Pharma a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates China Pharma as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

Highlights from TheStreet Ratings analysis on CPHI go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, CHINA PHARMA HOLDINGS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • CHINA PHARMA HOLDINGS INC has improved earnings per share by 16.7% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, CHINA PHARMA HOLDINGS INC swung to a loss, reporting -$0.45 versus $0.10 in the prior year.
  • CPHI, with its decline in revenue, slightly underperformed the industry average of 4.6%. Since the same quarter one year prior, revenues fell by 14.1%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • 41.65% is the gross profit margin for CHINA PHARMA HOLDINGS INC which we consider to be strong. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -33.63% is in-line with the industry average.
  • Net operating cash flow has significantly increased by 124.81% to $2.49 million when compared to the same quarter last year. In addition, CHINA PHARMA HOLDINGS INC has also vastly surpassed the industry average cash flow growth rate of -18.54%.

You can view the full analysis from the report here: China Pharma Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

3 Health Care Stocks Nudging The Sector Higher

3 Drugs Stocks Nudging The Industry Higher

3 Health Care Stocks Pushing The Sector Higher

3 Stocks Improving Performance Of The Drugs Industry